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Pharmacologic Modulation of Hand Pain in Osteoarthritis
A Double-Blind Placebo-Controlled Functional Magnetic Resonance Imaging
Study Using Naproxen
Duncan Sanders,1 Kristina Krause,2 Jonathan O’Muircheartaigh,3 Michael A. Thacker,4
John P. Huggins,5 William Vennart,5 Nathalie J. Massat,6 Ernest Choy,7
Steven C. R. Williams,3 and Matthew A. Howard3
Objective. In an attempt to shed light on manage-
ment of chronic pain conditions, there has long been a
desire to complement behavioral measures of pain
perception with measures of underlying brain mecha-
nisms. Using functional magnetic resonance imaging
(fMRI), we undertook this study to investigate changes
in brain activity following the administration of
naproxen or placebo in patients with pain related to
osteoarthritis (OA) of the carpometacarpal (CMC)
joint.
Methods. A placebo-controlled, double-blind,
2-period crossover study was performed in 19 individu-
als with painful OA of the CMC joint of the right hand.
Following placebo or naproxen treatment periods, a
functionally relevant task was performed, and behav-
ioral measures of the pain experience were collected in
identical fMRI examinations. Voxelwise and a priori
region of interest analyses were performed to detect
between-period differences in brain activity.
Results. Significant reductions in brain activity
following treatment with naproxen, compared to pla-
cebo, were observed in brain regions commonly associ-
ated with pain perception, including the bilateral pri-
mary somatosensory cortex, thalamus, and amygdala.
Significant relationships between changes in perceived
pain intensity and changes in brain activity were also
observed in brain regions previously associated with
pain intensity.
Conclusion. This study demonstrates the sensi-
tivity of fMRI to detect the mechanisms underlying
treatments of known efficacy. The data illustrate the
enticing potential of fMRI as an adjunct to self-report
for detecting early signals of efficacy of novel therapies,
both pharmacologic and nonpharmacologic, in small
numbers of individuals with persistent pain.
Osteoarthritis (OA) is a major cause of long-
term disability (1). Traditionally characterized by struc-
tural degradation of one or more synovial joints, OA is
typically associated with pain, swelling, and stiffness (2).
Reduced manual dexterity and inability to perform tasks
due to symptoms affect quality of life and ability to
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function independently (3). Levels of pain and disability
experienced by patients often do not correspond to the
level of tissue damage observed in the affected joints (4),
suggesting involvement of central nervous system mech-
anisms in the generation of OA-related pain (5). Given
the prevalence of OA and an increasingly aging popula-
tion, there is a pressing need for more effective treat-
ments (6,7). Many commonly prescribed medications
are ill suited for long-term use due to side effects
including tolerance, dependency, and gastrointestinal
complications (8,9). While pain is always a personal
experience and subject to multiple psychosocial factors,
there has long been a desire to complement subjective
reports with reliable markers of pain perception and
treatment effectiveness (10,11).
Neuroimaging methodologies offer the potential
to meet these desires (12). Functional magnetic reso-
nance imaging (fMRI) provides a safe, noninvasive,
repeatable indirect measure of neural activity suitable
for use in crossover trial designs (12). Reports have
suggested that fMRI could demonstrate analgesic
effects in populations of patients with clinical pain,
adding value to conventional behavioral end points and
facilitating decision-making early in drug development,
reducing risk, development times, and cost (12). Exper-
imental fMRI studies have provided useful insights into
the neural mechanisms of drug action (for review, see
ref. 13). In order to fulfill this potential, fMRI must
depict the neural correlates of the response to analgesics
in patients experiencing persistent pain. Preliminary
studies in OA have shown promise in establishing neural
correlates of response to analgesics (14,15), but to date
these studies have been underpowered or lacked appro-
priate placebo control. In this study we investigated the
potential of fMRI as a “fit-for-purpose” measurement
technique in development of analgesics for persistent
pain.
We sought to determine the ability of fMRI to
detect changes in brain functioning following a 1-week
course of naproxen in individuals with OA of the first
carpometacarpal (CMC) joint. Naproxen is an estab-
lished, effective nonsteroidal antiinflammatory drug
(NSAID) labeled for treatment of OA-related symp-
toms in the UK (www.emc.medicines.org.uk). We aimed
to detect naproxen-induced changes in brain activity
using a functionally relevant task that evoked pain.
We hypothesized that task-evoked brain activity would
be reduced following administration of naproxen, com-
pared to placebo. In particular, we hypothesized that a
network of brain regions previously associated with
pain perception would display significant reductions
in activity following naproxen administration, during
the task load that induced the highest rating of pain
intensity.
PATIENTS AND METHODS
Design. This study was a placebo-controlled, double-
blind, 2-period crossover design undertaken in participants
with OA of the first CMC joint of the right hand.
Ethics. Ethical approval was obtained from The Joint
South London and Maudsley and The Institute of Psychiatry
NHS Research Ethics Committee (reference no. 10/H0807/
10). Written informed consent was obtained from all partici-
pants.
Participants. Participants were recruited from mul-
tiple sources, including national radio, local and national print
magazines, a university e-mail circular, and referrals from hos-
pital rheumatology and physiotherapy departments. All partic-
ipants visited on 4 occasions: screening, familiarization, and 2
scanning sessions (1 following each treatment period). All had
a confirmed diagnosis of OA of the first CMC joint of the right
hand according to American College of Rheumatology criteria
(16) and were right-hand dominant with a background pain
intensity score of 4 on an 11-point (0–10) numerical rating
scale (NRS) at screening or randomization. Normal exclusion
criteria for MRI applied (e.g., height and weight criteria,
presence of internal metal, claustrophobia). Several other
major exclusion criteria were also applied, including severe
pain elsewhere in the body that might impair the assessment of
OA-related pain, history of other severe acute or chronic
medical or psychiatric conditions, previous nonresponse to
naproxen for pain relief, increased risk of adverse reactions to
NSAIDs, inability to conform to lifestyle guidelines, and use of
prohibited medications (including analgesics other than
NSAIDs, paracetamol, or codeine) prior to and during study
participation. Detailed inclusion/exclusion criteria as well as
screening, blinding, and randomization information are pro-
vided in Supplementary Materials, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38987/abstract.
A total of 189 participants (131 women, 58 men)
completed a preliminary telephone interview; 36 met the
inclusion criteria for screening, and 23 were randomized into
the study. Four participants were excluded after randomiza-
tion, due to radiologic abnormalities, drug-related adverse
reactions, and an MRI hardware failure. Nineteen participants
(18 women, 1 man) ages 50–80 years (mean SD 60.72 6.44
years) were included in the final analysis set. All participants
who completed the study reported compliance with the dosing
regimen (Figure 1). (Approximately 30% of all prospects for
the study were male, but only 18% were screened. Exclusions
in men were predominantly health related, for example, severe
pain elsewhere in the body, other types of hand pain [e.g.,
repetitive strain disorder/trigger finger], contraindicating
medical/surgical histories, head trauma, and lifestyle guideline
exclusions.)
Procedure. All participants completed psychometric
and pain-related questionnaires at each session, including the
short form McGill Pain Questionnaire (MPQ) (17), the Beck
Depression Inventory II (BDI-II) (18), the Spielberger State-
Trait Anxiety Inventory (STAI) (19), and the Patient-Rated
Wrist and Hand Evaluation (PRWHE) (20).
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Screening. At the initial session patients underwent a
medical and comprehensive blood screening, and medication
history was ascertained. Urine drug screen and alcohol breath
tests were administered at every session to ensure no con-
founding drug or alcohol use. Participants also underwent a
clinical hand examination by a specialist physiotherapist.
Familiarization. During the familiarization and mea-
surement sessions, each participant underwent a “mock scan”
in a simulated MRI environment designed to reduce feelings
of anxiety and claustrophobia. During the mock scan, partici-
pants received training on the task they would perform during
actual fMRI sessions, including a complete “trial run” and
participant-specific calibration of the task.
Medication dosing. All participants underwent down-
titration of existing analgesic medications over a period of up
to 28 days. Following down-titration, all participants received a
14-day paper diary in which to record perceived pain intensity
every morning and evening using an 11-point (0–10) NRS and
to record any observations or changes relating to their hands
or general health. In the first 7 days, all participants were
administered placebo. In the remaining 7 days, participants
were randomly administered either naproxen (500 mg twice a
day) or matched placebo. Following the first fMRI session, all
participants received a further 7 days of placebo and then
either naproxen or placebo (crossed over from period 1) as
their second period of dosing. Naproxen has well-established
pharmacokinetics, with peak plasma concentration 2–4 hours
after ingestion and a plasma half-life of 12–15 hours (www.
emc.medicines.org.uk).
Functional MRI scanning sessions and followup. The
fMRI task was designed to evoke OA-related pain (see below).
After completion of the scanning session, medication contain-
ers and pain diaries were given for the second dosing period.
The final fMRI scanning session was identical to the first,
except that no further treatment was dispensed. Six additional
telephone checks were performed during the study to ensure
well-being and compliance, and a followup telephone interview
was conducted 2 weeks after the final fMRI session.
Task. The task involved squeezing a key-shaped pres-
sure device between the right thumb and index finger (lateral
pinch) of the affected hand, designed to mimic everyday
activities difficult for individuals with OA hand pain, such as
gripping or handling small objects (3). The lateral pinch device
was an MRI-compatible pressure transducer, to which par-
ticipants applied varying levels of pressure. The device was
calibrated for each participant during the familiarization ses-
sion to determine the maximum voluntary contraction (MVC)
for each individual, measured in kilopascals. MVC was de-
fined as the average of 3 lateral pinches at each participant’s
maximum effort. During the 23-minute event-related fMRI
task, participants were cued to perform the lateral pinch
(squeeze) at each of 3 different levels (10%, 40%, and 70%) of
their MVC. The target force to be applied and visual feedback
of the participant’s own applied force were provided via a
visual target and moving vertical line on a custom computer-
ized scale projected onto a screen located at the participant’s
feet.
In each trial, participants were instructed to squeeze
the device until they reached the displayed target and then
perform an isometric hold for 1 second. The time required to
reach the desired effort was recorded to account for variability
in motor task duration. Each trial cycle lasted for 24 seconds.
Stimulus onsets were jittered within the first 6 seconds of
each trial. In addition, 15 (5 per level of MVC) computerized,
horizontal visual analog scale (VAS) assessments of pain
intensity were presented pseudorandomly throughout the ex-
periment, during which participants rated their perceived pain
intensity during the last-performed squeeze. Participants per-
Figure 1. Overview of study procedures and experimental design.
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formed VAS assessments using a joystick in their left hand,
anchored at the left with “no pain” and at the right with “worst
pain imaginable.” The VAS was displayed for 9 seconds to
allow adequate response time, followed by a 12-second inter-
trial interval. In total, 60 trials were presented in each exper-
imental run—15 per percentage of MVC and 15 VAS ratings.
Illustrations of the pinch device, target display, and computer-
ized VAS are provided in Supplementary Figure 1, available
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38987/abstract.
Behavioral data analysis. Pain diary and psychometric
data were analyzed using SPSS version 19. Differences be-
tween treatments on the PRWHE, STAI, BDI-II, and short
form MPQ were assessed using paired t-tests.
In-scanner behavioral analyses. In-scanner VAS rat-
ings were analyzed using repeated-measures analysis of vari-
ance, with MVC level (10%/40%/70%) and treatment
(naproxen/placebo) as factors.
MRI data acquisition. MRI data were acquired on a
3T Signa HDx whole-body scanner (General Electric) fitted
with an 8-channel, phased-array receive-only head coil. A total
of 465 whole-brain T2*-weighted interleaved axial volumes
were acquired using echo-planar imaging. A high-resolution
T1-weighted 3-dimensional (3-D) spoiled gradient-recalled
acquisition in the steady state (SPGR) sequence was also
acquired for interparticipant registration. Finally, we sought to
investigate whether treatment-related variability in the blood
oxygen level–dependent (BOLD) response (21) might be
explained by its relationship to underlying changes in global
cerebral blood flow (CBF)—a possibility given the modulatory
effect of naproxen on prostaglandin production (22), which
in turn modulates vascular tone, blood pressure, and global
CBF. We assessed global CBF using a pulsed continuous
arterial spin–labeled (pCASL) perfusion MRI sequence ac-
quired immediately prior to fMRI at each session (23,24).
Acquisition order and parameters were identical in both
scanning sessions. Full details regarding all sequence para-
meters are provided in Supplementary Materials, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38987/abstract.
Functional MRI data preprocessing. Preprocessing
was conducted using Statistical Parametric Mapping software
(SPM8) (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/).
Preprocessing included motion correction, coregistration of
the 3-D SPGR image to the mean functional image, segmen-
tation, and normalization to Montreal Neurological Institute
(MNI152) template space. Spatial smoothing using a full-width
half-maximum Gaussian kernel of 8 mm, interleaved slice
timing correction, and high-pass temporal filtering (100 sec-
onds) were performed using FMRI Expert Analysis Tool
(FEAT) version 5.98 (www.fmrib.ox.ac.uk/fsl).
Functional MRI statistical analysis. Statistical ana-
lysis of fMRI data was carried out using FEAT. A generalized
linear model for each participant and session was constructed
to perform the voxelwise time series statistical analysis using
FSL-FILM. Event timings at 10%, 40%, and 70% MVC were
convolved with a double-gamma hemodynamic response func-
tion and its temporal derivative. Temporal autocorrelation
correction was used (25), and estimated motion parameters
were included as confound regressors. Individual participant
first-level contrast of parameter estimates (COPE) images,
under both naproxen and placebo conditions, were derived
for 10%, 40%, and 70% MVC. An intermediate second-level
fixed-effects analysis was performed to average the 10%, 40%,
and 70% MVC COPE images to take forward for higher-level
analysis.
Higher-level group fMRI statistical analysis. Higher-
level analysis was carried out using FSL-FLAME stage 1 with
robust outlier detection (26). A whole-brain mixed-effects
analysis was performed, using individual participants’ COPE
images derived from the second level as inputs, to compute
voxelwise paired t-tests comparing differences in evoked brain
activity between naproxen and placebo conditions. An addi-
tional confound regressor for medication administration order
was included in the model. Z (Gaussianized T/F) statistic
images were thresholded using clusters determined by Z 2.3
and a (Gaussian random field–corrected) cluster significance
threshold of P  0.05 (27).
Global CBF analysis. A measure of global CBF in each
session was defined as the mean of all gray matter voxels within
the 3-D pCASL volume. Differences in global CBF between
naproxen and placebo sessions were assessed using a paired
t-test in SPSS version 19. The significance threshold was set at
P  0.05.
Region of interest (ROI) analyses. Anatomic ROIs
in MNI space were derived from Harvard-Oxford Cortical/
Subcortical and Juelich Histological probabilistic atlases avail-
able within FSL. Based on a priori information regarding brain
activation related to pain (28), ROIs were created for the
thalamus, primary and secondary somatosensory cortices, hip-
pocampal formation, anterior and posterior insula, anterior
and posterior cingulate cortices, and amygdala in both hemi-
spheres. Probabilistic ROIs were thresholded to include voxels
more than 20% likely to represent their indicated anatomic
location, and were then binarized to become mask images.
For each participant, the mean value across all voxels
within the ROI mask was computed as a summary measure of
the BOLD response under naproxen and placebo conditions.
Values were extracted from first-level 70% MVC COPE
images, as we hypothesized that this would induce the highest
reported levels of pain intensity. For each ROI hemisphere,
summary measure data were analyzed using a paired t-test in
SPSS version 19. Right and left hemisphere data were analyzed
separately as their variances differed between hemispheres.
Mean values for each treatment and corresponding standard
errors were plotted for ROIs demonstrating significant treat-
ment differences. (A supplementary voxelwise analysis of
treatment effects using the 70% MVC class only is provided as
part of Supplementary Figure 2, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.38987/abstract.)
Pearson product-moment correlation coefficients
were computed in SPSS version 19 to assess the relationship
between treatment-induced changes in fMRI squeeze task–
related VAS pain intensity and treatment-induced changes
in mean BOLD responses in selected bilateral ROIs (thala-
mus, primary and secondary somatosensory cortices, anterior
and posterior insula) previously reported to relate to the
intensity of perceived pain (29,30). Treatment differences
(  naproxen  placebo) were derived for each participant.
The significance threshold for all ROI analyses was set at
P  0.05. Due to the exploratory nature of these analyses,
we did not correct for multiple comparisons. Post hoc sample
size calculations to detect significant treatment differences
(alpha level of 0.05, 2-tailed, power of 80%) in each ROI
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in each hemisphere were derived using G*Power version
3.12 (31).
RESULTS
Behavioral data (psychometry and pain diaries).
As determined using an NRS, daily pain intensity after 7
days of treatment with naproxen was significantly re-
duced compared to treatment with placebo (t[18]  3.2,
P  0.005), confirming the known analgesic properties
of naproxen (Figure 2A). The VAS, present pain inten-
sity (PPI), and sensory subsections of the short form
MPQ demonstrated significant reductions after admin-
istration of naproxen compared to placebo (VAS rating
t[18]  4.34, P  0.001; PPI rating t[18]  3.31, P 
Figure 2. A, Mean  SEM daily pain intensity determined using a numerical rating scale (NRS) in patients receiving active treatment (light gray;
placebo on days 1–7, naproxen on days 8–14) compared to patients receiving placebo (dark gray; placebo on days 1–14). B, Mean  SEM visual
analog scale (VAS) scores during the lateral pinch task. During the scanning visits, participants with painful osteoarthritis of the thumb were cued
to perform a lateral pinch (squeeze) at each of 3 different levels (10%, 40%, and 70%) of their maximum voluntary contraction (MVC).
Table 1. Summary of demographic characteristics and pain and psychometric assessments in the 19 study
patients
Variable, session* Range Mean  SD t(18) P†
Age, years 52.00–72.00 60.72 6.44 – –
Pain duration, years 0.50–17.00 4.03 4.05 – –
Baseline pain, 0–10 – –
Screening 2.00–7.00 4.53  1.43
Familiarization 1.00–8.00 4.21 1.81
MPQ VAS rating 4.34 0.001
Naproxen 9.00–57.00 23.68 11.6
Placebo 8.00–82.00 39.47 20.12
MPQ PPI rating 3.31 0.004
Naproxen 0.00–2.00 0.89 0.65
Placebo 1.00–2.00 1.52 0.51
MPQ sensory rating 3.34 0.004
Naproxen 1.00–17.00 5.73  3.94
Placebo 3.00–30.00 9.68  7.11
MPQ affective rating 1.42 0.17
Naproxen 0.00–3.00 0.21  0.71
Placebo 0.00–7.00 0.73  1.72
PRWHE 2.08 0.05
Familiarization 11.50–68.00 42.39 15.45
Naproxen 5.50–65.50 28.97  15.08
Placebo 14.00–73.50 35.92  17.56
Spielberger STAI state anxiety rating 1.61 0.12
Naproxen 36.00–80.00 47 11.36
Placebo 36.00–84.00 50.52  13.14
BDI-II depression rating 0.77 0.45
Screening 0.00–23.00 7.05  6.41
Naproxen 0.00–22.00 6.05  5.93
Placebo 0.00–26.00 7.05  6.6
* MPQ  McGill Pain Questionnaire; VAS  visual analog scale; PPI  present pain intensity;
PRWHE  Patient-Rated Wrist and Hand Evaluation; STAI  State-Trait Anxiety Inventory; BDI-II 
Beck Depression Inventory II.
† Two-tailed.
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0.004; sensory rating t[18]  3.34, P  0.004). No
differences were observed for affective ratings on the
short form MPQ (t[18]  1.42, P  0.17). Measures of
wrist and hand pain and function (the PRWHE) were
significantly improved following administration of
naproxen compared to placebo (t[18]  2.08, P 
0.05). No significant differences between treatments
were observed for state anxiety (the STAI-S) (t[18] 
1.61, P  0.12) or depression (the BDI-II) (t[18] 
0.77, P  0.45), both of which were in the normal
range. Psychometric data are summarized in Table 1.
In-scanner behavioral data. We sought to inves-
tigate differences between naproxen and placebo treat-
ments in in-scanner self-reported pain measures. VAS
scores were significantly reduced following administra-
tion of naproxen compared to placebo (F[1,18]  10.61,
P  0.004) (Figure 2B). Participants’ levels of squeeze
(10%, 40%, and 70% MVC) induced a significant in-
crease in VAS scores (Greenhouse-Geisser–corrected
F[1.115,20.07]  12.83, P  0.001) (Figure 2B). There
was no interaction between levels of squeeze and treat-
ment. Task performance at 70% MVC evoked the
highest perceived pain intensity scores (mean  SEM
VAS score 37.61  4.64 for placebo and 25.379  4.06
for naproxen), providing an appropriate rationale for its
use in the ROI analysis.
Neuroimaging. Effects of naproxen on global CBF.
Differences between naproxen and placebo conditions
in global CBF were not significant (t[18]  1.3, P 
0.2), suggesting that BOLD signal treatment differences
were unlikely to be caused by generalized vascular
effects.
Whole-brain voxelwise analysis. Whole-brain
analyses of task performance fMRI data were per-
formed. Using the average of all levels of load (10%,
40%, and 70% MVC) as an input for each participant in
each session, significant reductions in BOLD signal
following treatment with naproxen, compared to pla-
cebo, were observed in a distributed network of brain
regions (see Supplementary Table 1 and Supplementary
Figure 2, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
Figure 3. A priori region of interest analysis. Adjacent to each image are corresponding left (L) and right (R) hemisphere mean  SEM blood
oxygen level–dependent (BOLD) responses for patients receiving placebo (bright red/bright blue) and patients receiving naproxen (light red/light
blue).   P  0.05. S2  secondary somatosensory cortex; S1  primary somatosensory cortex.
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art.38987/abstract). Several of these brain regions were
those that we had identified a priori as being important
in the cerebral representation of pain. We observed a
cluster in the left primary somatosensory cortex and a
smaller cluster in the right primary somatosensory cor-
tex. A further large cluster was identified in the thalamus
bilaterally that extended anteriorly into bilateral caudate
nuclei and the left nucleus accumbens and inferiorly into
the left midbrain in an area approximating that of the
substantia nigra. Further reductions were observed in
the right insula, extending to the temporal lobe, and
bilaterally in the amygdalae. We also observed reduc-
tions in the right and left frontal lobes and occipital
cortices, extending inferiorly into the cerebellum and the
posterior aspect of the pons. We did not observe any
relative BOLD signal increases following naproxen ad-
ministration compared to placebo.
ROI analysis. Significant naproxen-mediated re-
ductions in BOLD signal intensity were identified in the
amygdala, hippocampal formation, thalamus, primary
somatosensory cortex, and posterior cingulate cortex ROIs
bilaterally. Further reductions in the right hemisphere
only were observed in the anterior and posterior insula
cortices and in the secondary somatosensory cortex.
Figure 3 illustrates the mean values in significant ROIs
at placebo and naproxen sessions. Results of the pair-
wise t-tests for the treatment differences are detailed in
Table 2.
Exploring the relationship between treatment-
induced changes in task-related VAS pain intensity and
mean BOLD responses demonstrated positive correla-
tions in the primary and secondary somatosensory cor-
tices bilaterally and in the left thalamus (contralateral to
the affected hand). Representative plots of these rela-
tionships (Figure 4) illustrate that reductions in BOLD
response following naproxen treatment were associated
with reductions in perceived pain intensity. Post hoc
calculations of the sample size needed to detect signifi-
cant treatment effects varied considerably between
ROIs, ranging from a minimum of 16 participants (left
amygdala and left thalamus) to a maximum of 112
participants (right anterior cingulate cortex) (Table 2).
DISCUSSION
We have demonstrated the sensitivity of BOLD
fMRI to detect the effects of naproxen, an analgesic of
known efficacy, in a group of individuals with pain
secondary to OA of the CMC joint. Local reductions
in BOLD signal were identified in brain regions com-
monly associated with the experience of pain (28),
several of which we hypothesized a priori to show
Table 2. A priori ROI analysis*
ROI
Mean response
for placebo
treatment
Mean response
for naproxen
treatment
Treatment
difference
Standard error
of treatment
difference t(18)
P for
t(18)†
Pearson’s r
(n  19)‡
P for
Pearson’s r†
Sample
size§
ACC (L) 132.81 78.08 54.73 43.57 1.256 0.225 – – 97
ACC (R) 134.38 85.97 48.41 41.75 1.160 0.261 – – 112
AMY (L) 100.57 6.97 93.60 28.53 3.281 0.004 – – 16
AMY (R) 127.35 18.40 108.95 33.85 3.219 0.005 – – 17
HF (L) 57.72 33.81 91.54 33.65 2.720 0.014 – – 23
HF (R) 84.44 17.79 102.23 38.32 2.668 0.016 – – 23
aINS (L) 189.50 129.33 60.18 39.16 1.537 0.142 0.109 0.657 66
aINS (R) 256.77 172.95 83.82 33.18 2.527 0.021 0.188 0.440 26
pINS (L) 84.95 30.50 54.45 40.08 1.359 0.191 0.275 0.255 83
pINS (R) 91.15 15.19 106.34 33.72 3.154 0.005 0.015 0.952 18
PCC (L) 80.31 31.21 111.51 49.16 2.268 0.036 – – 31
PCC (R) 79.04 37.22 116.26 47.20 2.463 0.024 – – 27
S1 (L) 489.29 368.04 121.25 55.15 2.198 0.041 0.590 0.008 33
S1 (R) 158.06 72.13 85.93 39.10 2.198 0.041 0.484 0.036 33
S2 (L) 190.13 136.42 53.71 41.09 1.307 0.208 0.646 0.003 90
S2 (R) 177.96 88.88 89.09 33.38 2.668 0.016 0.585 0.008 23
TH (L) 181.76 40.95 140.81 42.21 3.336 0.004 0.460 0.048 16
TH (R) 161.75 36.81 124.94 40.57 3.080 0.006 0.427 0.070 18
* Shown are analyses of the following regions of interest (ROIs) in left (L) and right (R) hemispheres: anterior cingulate cortex (ACC), amygdala
(AMY), hippocampal formation (HF), anterior insula (aINS), posterior insula (pINS), posterior cingulate cortex (PCC), primary somatosensory
cortex (S1), secondary somatosensory cortex (S2), and thalamus (TH).
† Two-tailed.
‡ Pearson’s product-moment correlation coefficient for relationships between treatment-related differences in the magnitude of the blood oxygen
level–dependent signal and differences in perceived pain intensity measured by in-scanner visual analog scale recordings.
§ Post hoc sample size calculations (alpha level of 0.05, power of 80%) for each ROI.
NAPROXEN MODULATES BRAIN REPRESENTATION OF EVOKED PAIN IN HAND OA 747
changes in response to analgesia. Changes in treatment-
related VAS indices of pain intensity correlated with
changes in BOLD response in several of these brain
regions. These findings demonstrate that BOLD fMRI
adds value to conventional self-report measures, offer-
ing a mechanistic understanding of both pain and treat-
ment response (11).
Reductions in BOLD response were identified
in a distributed network of brain regions following
administration of naproxen, compared to placebo. These
effects were identified in a real-world sample of patients
with painful OA, within the constraints of a fully blinded
crossover experimental design. Given the location of
reductions in BOLD response following naproxen treat-
ment and the relationship in the thalamus and primary
and secondary somatosensory cortices between changes
in BOLD signal intensity and perceived pain, we infer
that our fMRI findings represent an analgesic effect of
naproxen on OA-related evoked pain. The absence of a
significant treatment effect on global CBF provides
confidence that treatment-derived BOLD signal changes
were most likely driven via mechanisms of neurovascular
coupling, rather than via a more generalized global
increase in CBF (32). We recommend acquisition of
imaging data using multiple fMRI modalities, alongside
conventional behavioral end points, in order to best
understand pain and analgesic responses (11).
Our results build on those of earlier studies of
experimental, acute, and persistent pain conditions
treated with various analgesic medications, in which
treatment effects have been demonstrated by fMRI
(e.g., see refs. 33–35). For the first time, we have
demonstrated a robust effect of naproxen on evoked
stimulation of pain in the CMC joint with OA. Previous
attempts to use pain secondary to OA as a clinical model
to assess analgesic effects by fMRI are difficult to
interpret, given that these effects were examined in so
few patients. The intention of Parks et al (15) to perform
a larger fMRI study to evaluate the treatment effects of
valdecoxib, a cyclooxygenase 2 inhibitor, was hampered
by the withdrawal of this agent from the US market. In
a subgroup of only 6 participants, those investigators
reported a significant effect of treatment on behavioral
indices of background/spontaneous pain but not evoked
pain. Interrelationships between drug concentrations,
perceived indices of spontaneous pain, and BOLD ac-
tivity were also described, but caution should be exer-
cised given their derivation from so few participants.
While Baliki et al (14) reported treatment effects in their
comparison of the effects of lidocaine on chronic low
back pain (n  7) and evoked knee OA pain (n  5) in
the medial prefrontal cortex and thalamus, respectively,
the authors acknowledge limitations in that study. Due
to small sample sizes, statistical handling of the data
limited treatment-related inferences to the study sam-
ples rather than to the clinical populations that they
represented, and the study had no placebo arm or a
control for potential treatment order effects.
Our work adds new knowledge to the field by
demonstrating an observable treatment effect in a larger
cohort of participants, in a study that was appropriately
Figure 4. Scatterplots showing the relationship between the change
(naproxen condition  placebo condition) in BOLD responses within
a particular region of interest (y-axis) and the change in visual analog
scale (VAS) scores collected during the task (x-axis). Plus signs
represent individual patients. See Figure 3 for other definitions.
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double blinded and placebo controlled. Post hoc power
calculations from this study using a priori–defined ROIs
indicated that a minimum of 16 individuals with OA of
the CMC joint are needed in order to identify a treat-
ment effect on evoked pain. A sample size of 16 was
sufficient only in the thalamus and amygdala contralat-
eral to the affected hand. We included these calculations
to guide others in powering future studies, but we
recognize that sample sizes may change due to factors
including body site, severity of OA pain, paradigm
design, and analgesic effect size. It is an unrealistic
expectation that treatment effects will modulate brain
responses either in all brain regions or in equal magni-
tude across them. We have shown that changes in brain
response relate to perceived pain relief; however, we
speculate that the magnitude, direction, and spatial
location of these changes are likely to represent a
composite generalized “analgesic effect” and response
characteristics unique to the analgesic under assessment.
In light of increasing evidence of the impact of persistent
pain states on both brain structure and function (36,37),
use of anatomically defined ROIs, while unbiased (38),
may also partially account for variability in required
sample sizes across ROIs. However, given the broad
acknowledgment that pain is a multifaceted experience
underpinned by a complex network of brain regions (39),
it is of course overly simplistic to ascertain treatment
effects from single ROIs in isolation.
A critical quality provided by the use of neuro-
imaging end points is the value that they add to conven-
tional behavioral indices, providing mechanistic corre-
lates of persistent pain (24) and treatment effects.
Previous studies (15,40) have shown perturbed affective
responses to pain in OA; these have recently been
theorized to be maladaptive assessments of and re-
sponses to pain as a threat to homeostatic body func-
tioning (24). Subtle variations in the location of su-
praspinal pain responses in these studies may reflect
heterogeneity in clinical pain states, but together they
add weight to a developing view that persistent OA pain
may be, at least in part, maintained by changes in central
as well as peripheral nervous system functioning
(14,15,24,40). Neuroimaging reports have also described
altered functioning of endogenous pain control mecha-
nisms in individuals with painful OA. A recent fMRI
study (5) showed the presence of neuropathic-like symp-
toms in patients with OA, using the PainDETECT
questionnaire (41). When fMRI was combined with
quantitative sensory testing, hyperalgesic responses to
punctate stimuli were associated with significant peri-
aqueductal gray matter activity, leading the authors to
interpret that the periaqueductal gray matter has a role
in central sensitization in at least some patients with
painful hip OA. Similarly, our own work examining
background pain in individuals with painful hand OA,
compared to healthy controls, showed differential CBF
between groups in the periaqueductal gray matter and
other descending modulatory systems in the midbrain
and brainstem (24).
These findings provide important insights for
interventions aimed at the reduction of OA-related pain,
which currently remain focused on reducing or eliminat-
ing potential peripheral generators of nociception, for
example, joint replacement surgery (42,43). Outcomes
of these interventions are not always satisfactory for
individuals (for review, see ref. 44), which may be due in
part to supraspinal pain mechanisms remaining essen-
tially uncharacterized and untreated. In this work, we
did not find a modulatory effect of naproxen in these
regions. Type II errors aside, these null findings suggest
the working hypothesis that the analgesic effect of
naproxen does not modulate descending pain control
system responses to evoked pain. Specifically designed
new studies will be needed to test this.
In this study, we combined a “gold standard”
pharmacologic MRI analgesic design methodology
with a novel functional task and a mock scan protocol.
This design aims to account for additional influences on
BOLD response, including treatment order, task de-
mands, anxiety, mood, and placebo responses. Psycho-
metric data on anxiety and depression were stable across
sessions, reducing the likelihood that they influenced the
fMRI results. Our chosen task differs from conventional
evoked-response paradigms in that pain responses are
elicited with an accompanying motor component. How-
ever, in light of recent comments that pain may repre-
sent an actual or perceived threat to the body (45,46), we
speculate that experimental paradigms that promote
genuine pain-provoking actions, rather than those that
elicit responses to on/off noxious stimulation, may rep-
resent a more comprehensive cerebral fingerprint of
pain response in OA (47).
In summary, our study demonstrates the sensitiv-
ity of BOLD fMRI to detect the mechanisms underlying
treatments of known efficacy in OA. The locations of
the effects were specific and physiologically plausible,
and treatment-related changes in VAS scores were
related to changes in BOLD response in brain regions
underpinning sensory discriminative aspects of the pain
experience. These results demonstrate the enticing po-
tential of fMRI as an adjunct to self-report for detection
of early signals of efficacy of novel pharmacologic and
nonpharmacologic treatments, in small numbers of indi-
viduals with persistent pain (see refs. 12 and 48), which
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in turn may provide them with reduced pain and in-
creased quality of life.
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Erratum
In the article by Jacobe et al published in the November 2014 issue of Arthritis & Rheumatology (pages
31703177), a row listing the (nonexistent) allele DQA1*03:00 was inadvertently included in Tables 3, 5, and
6, as the result of a typographical error. The number of patients with morphea (overall, generalized, or linear)
who had the allele as shown in Tables 3, 5, and 6 was referring to the allele DQA1*03. DQA1*03 is quite
common in the population overall, and the percentage of subjects who had this allele did not differ
significantly between morphea patients and controls. Therefore, this line should not have been included in
these tables at all, as the tables were meant to list only alleles positively or negatively associated with
morphea. Additionally, required corrections to article text are as follows: On page 3173, the sentence
“HLA–DQA1*03:00 was present exclusively in patients with morphea” should not have been included. On
page 3173, the sentence “The risk association of HLADQB1*02:01 and DQA1*03:00 was maintained in the
Caucasian patient subset, with the ORs and the proportion of cases with each allele being similar to those
in the overall group analysis, implying that the association of these risk alleles was with the group of morphea
cases overall” should have read “The risk association of HLADQB1*02:01 was maintained in the Caucasian
patient subset, with the OR and the proportion of cases with this allele being similar to that in the overall
group analysis, implying that the association of this risk allele was with the group of morphea cases overall.”
On page 3174, the sentence “In comparing patients with generalized morphea and controls (Table 5), the
same HLA class I and class II alleles were present as when overall cases were compared with controls,
including DQA1*03:00, DQB1*02:01, C*08, and C*15” should have read “In comparing patients with
generalized morphea and controls (Table 5), the same HLA class I and class II alleles were present as when
overall cases were compared with controls, including DQB1*02:01, C*08, and C*15.”
We regret the errors.
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